Drug-Eluting Stents (DES) remain a cornerstone of interventional cardiology, combining mechanical scaffolding with localized drug delivery to prevent restenosis. This session explores DES technology, pharmacology, clinical evidence, implantation techniques, and long-term outcomes. As the field evolves rapidly, specialists increasingly seek a structured cardiology conference to stay updated on next-generation platforms and best practices.

The description reviews the evolution from bare-metal stents to first-, second-, and third-generation DES, highlighting improvements in polymer biocompatibility, strut thickness, drug kinetics, and stent flexibility. Participants will understand how antiproliferative agents such as everolimus, zotarolimus, sirolimus, and biolimus alter smooth muscle proliferation and neointimal hyperplasia.

A major part focuses on implementing advanced DES implantation strategies, including lesion preparation, calcium modification, stent sizing, deployment techniques, post-dilation, and optimization using IVUS and OCT. Participants will learn why imaging-guided PCI reduces restenosis, thrombosis, and target lesion failure. Complex scenarios—such as bifurcation stenting, left main disease, long lesions, in-stent restenosis, and small-vessel disease—are discussed in detail.

The session also examines evidence on DAPT duration, polymer-free stents, bioresorbable scaffolds, and high-bleeding-risk patient strategies. Participants will explore how DES performance varies in diabetics, CKD patients, elderly individuals, and those requiring complex revascularization.

Future developments include ultrathin stents, bioengineered surfaces, metal-alloy innovations, drug-coated balloons, and platform designs enabling easier vessel healing. By completion, attendees will feel confident selecting and optimizing DES therapy tailored to individual patient anatomy and clinical needs.